201 related articles for article (PubMed ID: 18448280)
1. Aromatase inhibitors and the endometrium.
Cohen I
Maturitas; 2008 Apr; 59(4):285-92. PubMed ID: 18448280
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of postmenopausal breast cancer patients following discontinuation of tamoxifen therapy.
Markovitch O; Tepper R; Fishman A; Aviram R; Cohen I
Maturitas; 2008 Apr; 59(4):387-93. PubMed ID: 18490117
[TBL] [Abstract][Full Text] [Related]
3. Long-term "protective" effect of aromatase inhibitors on the endometrium of postmenopausal breast cancer patients.
Markovitch O; Tepper R; Fishman A; Aviram R; Cohen I
Breast Cancer Res Treat; 2009 Jan; 113(2):321-6. PubMed ID: 18297393
[TBL] [Abstract][Full Text] [Related]
4. Update on aromatase inhibitors in breast cancer.
Gould RE; Garcia AA
Curr Opin Obstet Gynecol; 2006 Feb; 18(1):41-6. PubMed ID: 16493259
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis of pre-operative aromatase inhibitor versus tamoxifen in postmenopausal woman with hormone receptor-positive breast cancer.
Seo JH; Kim YH; Kim JS
Cancer Chemother Pharmacol; 2009 Jan; 63(2):261-6. PubMed ID: 18365197
[TBL] [Abstract][Full Text] [Related]
6. Aromatase inhibitors reverse tamoxifen induced endometrial ultrasonographic changes in postmenopausal breast cancer patients.
Markovitch O; Tepper R; Fishman A; Aviram R; Cohen I
Breast Cancer Res Treat; 2007 Jan; 101(2):185-90. PubMed ID: 16897434
[TBL] [Abstract][Full Text] [Related]
7. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment.
Duffy S; Jackson TL; Lansdown M; Philips K; Wells M; Pollard S; Clack G; Coibion M; Bianco AR
Hum Reprod; 2006 Feb; 21(2):545-53. PubMed ID: 16210385
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant endocrine treatment of early breast cancer.
Lønning PE
Hematol Oncol Clin North Am; 2007 Apr; 21(2):223-38. PubMed ID: 17512446
[TBL] [Abstract][Full Text] [Related]
9. Endometrial pathologies associated with postmenopausal tamoxifen treatment.
Cohen I
Gynecol Oncol; 2004 Aug; 94(2):256-66. PubMed ID: 15297160
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen use and endometrial lesions: hysteroscopic, histological, and immunohistochemical findings in postmenopausal women with breast cancer.
Dibi RP; Zettler CG; Pessini SA; Ayub AV; de Almeida SB; da Silveira GP
Menopause; 2009; 16(2):293-300. PubMed ID: 19034048
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen and aromatase inhibitors differentially affect vascular endothelial growth factor and endostatin levels in women with breast cancer.
Holmes CE; Huang JC; Pace TR; Howard AB; Muss HB
Clin Cancer Res; 2008 May; 14(10):3070-6. PubMed ID: 18483373
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant and extended adjuvant use of aromatase inhibitors: reducing the risk of recurrence and distant metastasis.
Gligorov J; Pritchard K; Goss P
Breast; 2007 Dec; 16 Suppl 3():S1-9. PubMed ID: 18061455
[TBL] [Abstract][Full Text] [Related]
13. Sequential therapy with tamoxifen and aromatase inhibitors in early-stage postmenopausal breast cancer: a review of the evidence.
Litsas G
Oncol Nurs Forum; 2008 Jul; 35(4):714-21. PubMed ID: 18591176
[TBL] [Abstract][Full Text] [Related]
14. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Wardley AM
Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
[TBL] [Abstract][Full Text] [Related]
15. [MR Imaging of the pelvis in the diagnosis of the endometrium in breast cancer patients in tamoxifen therapy].
Hauth E; Libera H; Kimmig R; Forsting M
Rofo; 2006 Mar; 178(3):316-23. PubMed ID: 16508840
[TBL] [Abstract][Full Text] [Related]
16. Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant tamoxifen.
Booth CM; Pater JL; Goss PE
Cancer; 2007 May; 109(9):1927-8; author reply 1928. PubMed ID: 17354227
[No Abstract] [Full Text] [Related]
17. Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer.
Chlebowski RT
Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():25-34. PubMed ID: 19101792
[TBL] [Abstract][Full Text] [Related]
18. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials.
Cuppone F; Bria E; Verma S; Pritchard KI; Gandhi S; Carlini P; Milella M; Nisticò C; Terzoli E; Cognetti F; Giannarelli D
Cancer; 2008 Jan; 112(2):260-7. PubMed ID: 18041059
[TBL] [Abstract][Full Text] [Related]
19. Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor.
Yamamoto Y; Masuda N; Ohtake T; Yamashita H; Saji S; Kimijima I; Kasahara Y; Ishikawa T; Sawaki M; Hozumi Y; Iwase H
Breast Cancer; 2010 Oct; 17(4):254-60. PubMed ID: 19685269
[TBL] [Abstract][Full Text] [Related]
20. Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors.
Garuti G; Cellani F; Centinaio G; Montanari G; Nalli G; Luerti M
Gynecol Oncol; 2006 Nov; 103(2):599-603. PubMed ID: 16750259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
